Background: Optimal treatment strategies for retroperitoneal leiomyosarcoma (RPLMS),
| INTRODUCTION
Approximately 15% of soft tissue sarcomas originate in the retroperitoneum. 1 The average annual incidence of retroperitoneal (RP) sarcoma is approximately 2.7 cases per million people. 2 RP sarcoma is a heterogeneous disease entity that consists of a large number of different histologic subtypes, 3 most commonly, liposarcoma, leiomyosarcoma (LMS), undifferentiated pleomorphic sarcoma, and solitary fibrous tumor. 4, 5 Each histologic subtype has unique behavioral characteristics and treatment outcomes 6 ; therefore, histology should be used to guide treatment. 7 LMS accounts for 15-30% of RP sarcomas, 4, [8] [9] [10] and patients with RP LMS have a significant risk of distant metastasis (>50%) but a lower risk of local recurrence than patients with other RP sarcomas, 8, 9 particularly in comparison to RP liposarcomas which have a predominantly local pattern of recurrence. 5 Surgical resection is the standard treatment for all localized RP sarcomas, but there is some controversy about whether resection should include uninvolved organs near the primary tumor. 11 Although a recent large study identified prognostic factors for patients who undergo surgery for primary RP sarcomas, 5 information specific to RP LMS is limited. Moreover, the optimal treatment strategy for recurrent RP LMS is unknown, especially regarding whether and when resection is appropriate. We sought to investigate surgical outcomes and recurrence patterns of RP LMS and the impact of salvage surgery in treating recurrent disease.
| RESULTS
We identified 266 patients with RP LMS who were evaluated at MDACC during the period studied. Sixty-two patients had synchronous metastatic disease, and 21 patients had unresectable disease at the initial presentation. Both of these groups were excluded from the study. Of the 183 patients who underwent surgery, 11 underwent palliative (R2) resection, and 172 underwent complete resection of the primary disease. Patient and tumor characteristics are summarized in 
| Prognostic factors for survival
Results of univariate and multivariate analyses to identify prognostic factors for OS and RFS are summarized in Tables 2 and 3 . Since no factors remained in the models by stepwise methods, multivariate analyses were performed by entering all listed covariates. There were no variables found to be significant to predict OS or RFS.
| Recurrence pattern and impact of salvage surgery
Of all 172 patients that underwent complete excision of the primary Results of univariate and multivariate analyses performed to identify predictors of PFS after salvage surgery are shown in Table 4 . 
| DISCUSSION
We report a retrospective study of patients with surgically resected RP LMS. To our knowledge, this is the first to report surgical outcomes in patients being treated for recurrent RP LMS. We observed that following resection, RP LMS recurred more frequently at distant sites than locally and that the most common sites of recurrence were the lungs, liver, and skin or soft tissue. Salvage surgery for recurrent disease was associated with improved OS, and location (distant or local) or multifocality of the recurrent disease was not associated with OS. However, the second recurrence rate was high; cure was rare after recurrence. A disease-free interval shorter than 12 months from the time of surgical resection of the primary tumor until initial tumor recurrence was the only factor that predicted PFS, but the timing of and lung was the most common site of recurrence, followed by the liver.
Multivariate analysis of risk factors for recurrence showed that size >10 cm and R1 resection were associated with local recurrence, and size >10 cm and high grade histology were associated with distant recurrence. The benefit of perioperative therapy was not assessed. 16 We observed an association between salvage surgery for recurrent RP LMS and improved survival in this study; however, the true benefit of salvage surgery for recurrent RP sarcomas remains controversial. There are a few reports that have analyzed the potential benefit of salvage surgery for RP sarcomas; however, these reports do not distinguish amongst histologic subtypes.
Evidence specific to salvage surgery for RP LMS is limited. In a retrospective study of 377 RP sarcoma patients, including 59 and concluded that a second surgery was of limited benefit when local recurrence followed extended resection. 9 In contrast, in a single-institution retrospective study in which 57% of 61 patients with RP sarcomas who experienced local recurrence underwent salvage surgery, 17 Lewis et al 17 propensity score matching, perioperative chemotherapy was associated with shorter OS (40 months vs 52 months; P = 0.002). 19 However, owing to innate selection bias associated with this retrospective analysis, the clinical benefit of perioperative therapy remains unclear.
Future prospective study is warranted, and researchers should be aware that response to chemotherapy is distinct among different histologic subtypes of RP sarcomas.
A limitation of our study was its retrospective design, which results in unavoidable selection bias. Selection bias likely affected our finding of longer survival in patients who underwent salvage surgery.
To address the rarity of RP LMS, we included patients who underwent initial primary resection at other facilities, but this strategy may have also contributed to the selection bias. However, given the excellent survival after salvage surgery (median OS after recurrence, >5 years), we believe it would be inappropriate to perform a randomized controlled trial to test the benefit of salvage surgery in patients with recurrent RP LMS. Clearly, patient selection for salvage surgery is of paramount importance, and the results of our analysis should help such patient selection.
Strengths of our study are its single-institution design and our institution's status as a high-volume cancer center, which allowed us to include a relatively large number of patients with this rare disease.
We believe that our findings, which are specific to RP LMS, will help guide treatment strategies, especially for patients with recurrent disease.
In conclusion, we observed that RP LMS had a relatively low local recurrence rate and a high distant metastasis rate, supporting previous findings in smaller series. Salvage surgery for recurrent RP LMS was associated with improved OS. Short disease-free interval (<12 months) was a risk factor for PFS after salvage surgery, whereas multifocality, recurrence-to-salvage interval (<6 months vs ≥6 months), and type of recurrence (distant vs local) were not. We recommend that surgeons consider salvage surgery for patients with recurrent RP LMS, particularly when the recurrence occurs after a disease-free interval longer than 12 months from the time of initial tumor resection even if multifocal recurrent disease is present.
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